Literature DB >> 16170094

Longitudinal change in 99mTcHMPAO cerebral perfusion SPECT in Parkinson's disease over one year.

M J Firbank1, S Molloy, I G McKeith, D J Burn, J T O'Brien.   

Abstract

BACKGROUND: Brain perfusion deficits have been reported previously in subjects with Parkinson's disease in comparison with healthy controls.
OBJECTIVE: To carry out a longitudinal study of perfusion in patients with Parkinson's disease and controls to find areas showing a reduction in perfusion over one year.
METHODS: Two HMPAO cerebral perfusion scans were acquired one year apart in 30 subjects with Parkinson's disease (mean (SD) age, 76 (5) years) and 34 healthy comparison subjects (76 (7) years). Scans were normalised to the mean intensity in the cerebellum.
RESULTS: Using SPM99 within groups to investigate regions that showed a decrease in perfusion between scans, it was found that in Parkinson's disease subjects but not controls there was a significant cluster in the frontal lobe (Brodmann area 10) where perfusion decreased over the year.
CONCLUSIONS: The progressive frontal perfusion deficits in Parkinson's disease are consistent with results from previous structural and neuropsychological studies suggesting frontal lobe involvement and executive dysfunction even in early Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16170094      PMCID: PMC1739344          DOI: 10.1136/jnnp.2004.058685

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  7 in total

1.  SPECT neuroimaging and neuropsychological functions in different stages of Parkinson's disease.

Authors:  Anna Paschali; Lambros Messinis; Odysseas Kargiotis; Velissarios Lakiotis; Zinovia Kefalopoulou; Costantinos Constantoyannis; Panagiotis Papathanasopoulos; Pavlos Vassilakos
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-02-10       Impact factor: 9.236

2.  Neuropsychological functions and rCBF SPECT in Parkinson's disease patients considered candidates for deep brain stimulation.

Authors:  Anna Paschali; Lambros Messinis; Epameinondas Lyros; Costas Constantoyannis; Zinovia Kefalopoulou; Velissarios Lakiotis; Panagiotis Papathanasopoulos; Paulos Vassilakos
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-05-27       Impact factor: 9.236

3.  Tracking Parkinson's Disease over One Year with Multimodal Magnetic Resonance Imaging in a Group of Older Patients with Moderate Disease.

Authors:  Tracy R Melzer; Daniel J Myall; Michael R MacAskill; Toni L Pitcher; Leslie Livingston; Richard Watts; Ross J Keenan; John C Dalrymple-Alford; Tim J Anderson
Journal:  PLoS One       Date:  2015-12-29       Impact factor: 3.240

Review 4.  Imaging biomarkers in Parkinson's disease and Parkinsonian syndromes: current and emerging concepts.

Authors:  Usman Saeed; Jordana Compagnone; Richard I Aviv; Antonio P Strafella; Sandra E Black; Anthony E Lang; Mario Masellis
Journal:  Transl Neurodegener       Date:  2017-03-28       Impact factor: 8.014

5.  Discriminative pattern of reduced cerebral blood flow in Parkinson's disease and Parkinsonism-Plus syndrome: an ASL-MRI study.

Authors:  Lina Cheng; Xiaoyan Wu; Ruomi Guo; Yuzhou Wang; Wensheng Wang; Peng He; Hanbo Lin; Jun Shen
Journal:  BMC Med Imaging       Date:  2020-07-13       Impact factor: 1.930

Review 6.  Neuroimaging Advances in Parkinson's Disease and Atypical Parkinsonian Syndromes.

Authors:  Usman Saeed; Anthony E Lang; Mario Masellis
Journal:  Front Neurol       Date:  2020-10-15       Impact factor: 4.003

Review 7.  A systematic review of biomarkers for disease progression in Parkinson's disease.

Authors:  David J M McGhee; Pamela L Royle; Paul A Thompson; David E Wright; John P Zajicek; Carl E Counsell
Journal:  BMC Neurol       Date:  2013-04-12       Impact factor: 2.474

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.